Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Exploratory Clinical Study Evaluating EPI-003 Injection for the Treatment of Chronic Hepatitis B
Sponsor: Epigenic Therapeutics, Inc
Summary
This study is an open-label, 2-Part (Single Ascending Dose \[Part 1\] And Dose Expansion) study that will evaluate the safety of EPI-003 administered to patients with chronic infection with HBV (CHB). EPI-003 is a liver-targeted antiviral therapeutic for intravenous (IV) injection that is capable of precise epigenetic modifications of the HBV genome without causing mutations in the gene sequence itself.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2024-12-20
Completion Date
2026-12-31
Last Updated
2024-12-24
Healthy Volunteers
No
Conditions
Interventions
EPI-003
Intravenous (IV) infusion.
Locations (1)
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China